Certara (NASDAQ:CERT) Shares Gap Up After Analyst Upgrade

Certara, Inc. (NASDAQ:CERT)’s share price gapped up before the market opened on Friday after Robert W. Baird raised their price target on the stock from $9.00 to $13.00. The stock had previously closed at $10.51, but opened at $11.84. Robert W. Baird currently has a neutral rating on the stock. Certara shares last traded at $12.02, with a volume of 2,155,196 shares trading hands.

Other analysts have also recently issued reports about the company. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target for the company. Barclays lowered their target price on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday. Stephens reissued an “overweight” rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Institutional Investors Weigh In On Certara

Several large investors have recently made changes to their positions in CERT. Blue Trust Inc. boosted its stake in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock worth $56,000 after purchasing an additional 822 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock worth $253,000 after buying an additional 823 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after buying an additional 1,047 shares in the last quarter. Bank of Montreal Can raised its position in Certara by 9.1% in the 4th quarter. Bank of Montreal Can now owns 19,943 shares of the company’s stock valued at $212,000 after buying an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after acquiring an additional 1,866 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Trading Up 22.8 %

The business has a 50-day simple moving average of $11.61 and a two-hundred day simple moving average of $11.37. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -64.55, a P/E/G ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.